Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0002065630-25-000002
Filing Date
2025-05-01
Accepted
2025-05-01 16:29:48
Documents
4
Period of Report
2025-05-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1746131382.html 3  
1 FORM 3 wk-form3_1746131382.xml 3 1686
2 EX-24.DONNELLYPOA donnellypoaworkiva.htm EX-24.DONNELLYPOA 937
3 SIGNATURE donnellypoaworkiva001.jpg GRAPHIC 229066
4 SIGNATURE donnellypoaworkiva002.jpg GRAPHIC 89677
  Complete submission text file 0002065630-25-000002.txt   443256
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Issuer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address
Donnelly Brian J (Reporting) CIK: 0002065630 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-26642 | Film No.: 25903707